43 results
424B5
NKTX
Nkarta Inc
25 Mar 24
Prospectus supplement for primary offering
8:15pm
in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”);
reduced
8-K
EX-99.1
NKTX
Nkarta Inc
25 Mar 24
Regulation FD Disclosure
6:05am
Lymphodepletion Cyclophosphamide Fludarabine Efficacy assessment Dose 1 Dose 2 Dose 3 Dickinson, et al. Oral presentation at EHA 2023, program section
8-K
EX-99.1
hr2opc3 tu20e7
8 Jan 24
Regulation FD Disclosure
8:50am
8-K
EX-99.2
3unsnab7xhp3ijhg6o
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
8-K
EX-99.1
3fgtimudg
27 Jun 23
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
7:07am
PRE 14A
i2s dehprqv7
14 Apr 23
Preliminary proxy
5:00pm
8-K
EX-99.2
f2qdq4a6r80n4ym sv
5 Dec 22
Regulation FD Disclosure
7:39am
8-K
EX-99.1
c5uvly2qsthea
5 Dec 22
Regulation FD Disclosure
7:39am
424B5
4btji0bvavr
26 Apr 22
Prospectus supplement for primary offering
4:02pm
424B5
21merrh
25 Apr 22
Prospectus supplement for primary offering
4:03pm